| Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy. (NCT03137537) | Dana-Farber Cancer Institute | 2018-02-27 |
| A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer (NCT03392246) | Dana-Farber Cancer Institute | 2018-01-31 |
| HealthSmart: Promoting Healthy Lifestyles for Young Adult Cancer Survivors Using Educational Videos (NCT03340532) | Dana-Farber Cancer Institute | 2018-01-30 |
| Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer (NCT03414684) | Dana-Farber Cancer Institute | 2018-01-30 |
| Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer (NCT02876302) | Dana-Farber Cancer Institute | 2018-01-24 |
| Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer (NCT03316599) | Dana-Farber Cancer Institute | 2018-01-17 |
| A Nurse Led Project to Introduce Hand Lettering as a Form of Creative Art Expression to Patients in an Ambulatory Oncology Setting (NCT03291730) | Dana-Farber Cancer Institute | 2018-01-09 |
| Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation (NCT03244826) | Dana-Farber Cancer Institute | 2018-01-01 |
| Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors (NCT03333616) | Dana-Farber Cancer Institute | 2017-12-28 |
| Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy (NCT03070145) | Dana-Farber Cancer Institute | 2017-12-08 |
| Pembrolizumab in Neoplasms or Lymphomas (NCT03316573) | Dana-Farber Cancer Institute | 2017-12-07 |
| PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions (NCT03070236) | Dana-Farber Cancer Institute | 2017-12-01 |
| Physical Activity In Gastrointestinal Cancer (NCT03331406) | Dana-Farber Cancer Institute | 2017-12-01 |
| A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer (NCT03316586) | Dana-Farber Cancer Institute | 2017-11-30 |
| A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia (NCT03187262) | Dana-Farber Cancer Institute | 2017-11-27 |
| Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma (NCT03236428) | Dana-Farber Cancer Institute | 2017-11-24 |
| Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) (NCT03141671) | Dana-Farber Cancer Institute | 2017-11-24 |
| Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 (NCT03310879) | Dana-Farber Cancer Institute | 2017-11-21 |
| Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen) (NCT03328091) | Dana-Farber Cancer Institute | 2017-11-21 |
| Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer (NCT03294694) | Dana-Farber Cancer Institute | 2017-11-08 |
| Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL (NCT03319901) | Dana-Farber Cancer Institute | 2017-10-30 |
| Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer (NCT03289039) | Dana-Farber Cancer Institute | 2017-10-25 |
| A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia (NCT03225716) | Dana-Farber Cancer Institute | 2017-10-20 |
| Nivolumab Plus Ipilimumab in Thyroid Cancer (NCT03246958) | Dana-Farber Cancer Institute | 2017-10-03 |
| Palbociclib After CDK and Endocrine Therapy (PACE) (NCT03147287) | Dana-Farber Cancer Institute | 2017-09-05 |
| Post-Operative Ambulatory Challenge and Exercise (PACE) Trial (NCT03234933) | Dana-Farber Cancer Institute | 2017-08-02 |
| Cyclophosphamide and Alemtuzumab In Lymphoma (NCT03132584) | Dana-Farber Cancer Institute | 2017-07-30 |
| A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (NCT03152318) | Dana-Farber Cancer Institute | 2017-07-18 |
| Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN (NCT03085719) | Dana-Farber Cancer Institute | 2017-06-30 |
| SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (NCT03113643) | Dana-Farber Cancer Institute | 2017-06-26 |
| A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer (NCT03093272) | Dana-Farber Cancer Institute | 2017-06-23 |
| Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility Study (NCT03170648) | Dana-Farber Cancer Institute | 2017-06-19 |
| A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer (NCT03131206) | Dana-Farber Cancer Institute | 2017-06-19 |
| Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC (NCT03093428) | Dana-Farber Cancer Institute | 2017-06-09 |
| LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma (NCT03101254) | Dana-Farber Cancer Institute | 2017-06-06 |
| Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer (NCT03170206) | Dana-Farber Cancer Institute | 2017-05-31 |
| Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer (NCT03130439) | Dana-Farber Cancer Institute | 2017-05-26 |
| Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC (NCT03051672) | Dana-Farber Cancer Institute | 2017-05-22 |
| Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer (NCT03122717) | Dana-Farber Cancer Institute | 2017-05-09 |
| Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma (NCT03087019) | Dana-Farber Cancer Institute | 2017-04-25 |
| The HOPE Trial and the SMART Study (NCT03022032) | Dana-Farber Cancer Institute | 2017-04-12 |
| Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial (NCT03075072) | Dana-Farber Cancer Institute | 2017-04-10 |
| A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma (NCT03075527) | Dana-Farber Cancer Institute | 2017-04-10 |
| Qigong For PPSP In Breast Cancer Pain In Breast Cancer Survivors (NCT02848989) | Dana-Farber Cancer Institute | 2017-04-04 |
| Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (NCT02865135) | Dana-Farber Cancer Institute | 2017-03-30 |
| A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer (NCT03051659) | Dana-Farber Cancer Institute | 2017-03-22 |
| A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome (NCT03054896) | Dana-Farber Cancer Institute | 2017-03-08 |
| Reduction of Post Mastectomy Pain With the Jacki® Recovery Jacket (NCT02976103) | Dana-Farber Cancer Institute | 2017-03-07 |
| Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (NCT03020030) | Dana-Farber Cancer Institute | 2017-03-03 |
| Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors (NCT03065062) | Dana-Farber Cancer Institute | 2017-02-28 |
| Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy (NCT03060720) | Dana-Farber Cancer Institute | 2017-02-24 |
| A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 (NCT03032107) | Dana-Farber Cancer Institute | 2017-02-17 |
| Improving Communication Between Cancer Patients & Oncologists (NCT02969031) | Dana-Farber Cancer Institute | 2017-02-14 |
| A Study of Abemaciclib in Recurrent Glioblastoma (NCT02981940) | Dana-Farber Cancer Institute | 2017-02-09 |
| CISPLATIN + AZD-1775 In Breast Cancer (NCT03012477) | Dana-Farber Cancer Institute | 2017-01-18 |
| Pembrolizumab in Refractory Advanced Esophageal Cancer (NCT02971956) | Dana-Farber Cancer Institute | 2017-01-18 |
| Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors (NCT02581384) | Dana-Farber Cancer Institute | 2017-01-01 |
| Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation (NCT02867384) | Dana-Farber Cancer Institute | 2016-11-29 |
| Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone (NCT02880319) | Dana-Farber Cancer Institute | 2016-11-29 |
| Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy (NCT02956473) | Dana-Farber Cancer Institute | 2016-11-15 |
| Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer (NCT02912572) | Dana-Farber Cancer Institute | 2016-11-14 |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors (NCT02920996) | Dana-Farber Cancer Institute | 2016-11-11 |
| A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (NCT02873962) | Dana-Farber Cancer Institute | 2016-11-10 |
| Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity (NCT02919683) | Dana-Farber Cancer Institute | 2016-11-01 |
| A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma (NCT02903381) | Dana-Farber Cancer Institute | 2016-10-20 |
| Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy (NCT02903368) | Dana-Farber Cancer Institute | 2016-10-19 |
| A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency (NCT02873975) | Dana-Farber Cancer Institute | 2016-10-12 |
| Pembrolizumab in Metastatic Anal Cancer (NCT02919969) | Dana-Farber Cancer Institute | 2016-10-11 |
| A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma (NCT02919670) | Dana-Farber Cancer Institute | 2016-10-01 |
| Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma (NCT02909777) | Dana-Farber Cancer Institute | 2016-10-01 |
| Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma (NCT02916771) | Dana-Farber Cancer Institute | 2016-10-01 |
| A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma (NCT02852655) | Dana-Farber Cancer Institute | 2016-09-21 |
| Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer (NCT02865811) | Dana-Farber Cancer Institute | 2016-09-15 |
| Palbociclib With Everolimus + Exemestane In BC (NCT02871791) | Dana-Farber Cancer Institute | 2016-08-24 |
| Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome (NCT02670525) | Dana-Farber Cancer Institute | 2016-08-17 |
| Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma (NCT02724878) | Dana-Farber Cancer Institute | 2016-07-15 |
| Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies (NCT02853500) | Dana-Farber Cancer Institute | 2016-07-01 |
| A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer (NCT02661815) | Dana-Farber Cancer Institute | 2016-06-15 |
| A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors (NCT02795858) | Dana-Farber Cancer Institute | 2016-06-14 |
| Implementation of a System-level Tobacco Treatment Intervention (NCT02816697) | Dana-Farber Cancer Institute | 2016-06-01 |
| Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer (NCT02770014) | Dana-Farber Cancer Institute | 2016-06-01 |
| Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) (NCT02764541) | Dana-Farber Cancer Institute | 2016-05-24 |
| Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia (NCT02677324) | Dana-Farber Cancer Institute | 2016-05-09 |
| ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL (NCT02787369) | Dana-Farber Cancer Institute | 2016-05-01 |
| MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer (NCT02689401) | Dana-Farber Cancer Institute | 2016-05-01 |
| Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy (NCT02752009) | Dana-Farber Cancer Institute | 2016-04-26 |
| Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer (NCT02698891) | Dana-Farber Cancer Institute | 2016-04-07 |
| Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients (NCT02706249) | Dana-Farber Cancer Institute | 2016-04-01 |
| An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. (NCT02657343) | Dana-Farber Cancer Institute | 2016-03-09 |
| Gut Decontamination In Pediatric Allogeneic Hematopoietic (NCT02641236) | Dana-Farber Cancer Institute | 2016-03-01 |
| An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma (NCT02648997) | Dana-Farber Cancer Institute | 2016-03-01 |
| Hereditary Risk Factors for Thyroid Cancer (NCT02747888) | Dana-Farber Cancer Institute | 2016-03-01 |
| A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer (NCT02499497) | Dana-Farber Cancer Institute | 2016-02-29 |
| A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (NCT02623972) | Dana-Farber Cancer Institute | 2016-02-26 |
| Improving Surgical Decision-making in Young Women With Breast Cancer (NCT02644382) | Dana-Farber Cancer Institute | 2016-02-19 |
| Novel Social Media Intervention For Older Br CA Patients (NCT02639208) | Dana-Farber Cancer Institute | 2016-02-08 |
| BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors (NCT02656849) | Dana-Farber Cancer Institute | 2016-02-01 |
| A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer (NCT02657551) | Dana-Farber Cancer Institute | 2016-01-01 |
| Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing (NCT02604511) | Dana-Farber Cancer Institute | 2016-01-01 |
| The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer (NCT02653755) | Dana-Farber Cancer Institute | 2015-12-15 |